Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
Chemo-Sero-Therapeutic Research Institute, known as Kaketsuken, and Takeda Pharmaceutical will make additional flu vaccines to cover an expected shortage for 25 million people in a state-funded project to prepare for possible flu epidemics in Japan. The Ministry of Health, Labor…
To read the full story
Related Article
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kitasato Daiichi Cannot Secure Flu Vaccine Production Capacity for 20 Million People by State Project Deadline
March 10, 2014
- Kaketsuken Makes Another Bid to Fill Unmet Flu Vaccine Quota for 25 Million People
February 14, 2014
REGULATORY
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…